Buchumschlag

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Jason M. Samuels, Fei Ye, Rebecca Irlmeier, Heidi Silver, Gitanjali Srivastava, Matthew Spann
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Diabetes, Obesity and Metabolism
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide
von: Ebaa Al Ozairi, et al.
Veröffentlicht: (2025)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
von: Jason M. Samuels, et al.
Veröffentlicht: (2024)

Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
von: Søren Seier, et al.
Veröffentlicht: (2025)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
von: Alpana P. Shukla, et al.
Veröffentlicht: (2025)

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
von: Lauren Wilson, et al.
Veröffentlicht: (2026)

Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status
von: Franziska S. Ulrich, et al.
Veröffentlicht: (2026)

Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
von: Scott A. Coon, et al.
Veröffentlicht: (2025)

Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population
von: Adam Buckley, et al.
Veröffentlicht: (2024)

Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States
von: Reema Mody, et al.
Veröffentlicht: (2025)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
von: Michelle Look, et al.
Veröffentlicht: (2025)

Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
von: Manish R. Bhise, et al.
Veröffentlicht: (2025)

Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
von: Shanshan Hu, et al.
Veröffentlicht: (2024)

Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
von: Michael S. Kelly, et al.
Veröffentlicht: (2024)

Correction to “Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight”
Veröffentlicht: (2025)

Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence
von: Alexandra A. Weinreich, et al.
Veröffentlicht: (2025)

Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”
Veröffentlicht: (2024)

Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system
von: Ning Wang, et al.
Veröffentlicht: (2026)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
von: Domenica M. Rubino, et al.
Veröffentlicht: (2025)

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects
von: Malene Svoldgaard Sørensen, et al.
Veröffentlicht: (2025)

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial
von: Koutaro Yokote, et al.
Veröffentlicht: (2025)

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies
von: Reimar W. Thomsen, et al.
Veröffentlicht: (2025)

Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
von: Man Tang, et al.
Veröffentlicht: (2025)

Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study
von: Jheng‐Yan Wu, et al.
Veröffentlicht: (2025)

Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database
von: Theresa Hunter Gibble, et al.
Veröffentlicht: (2025)

Safety and effectiveness of tirzepatide during Ramadan fasting: Real‐world evidence from patients with type 2 diabetes in Bangladesh
von: Muhammad Hafizur Rahman, et al.
Veröffentlicht: (2025)

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study
von: Yusuke Minakata, et al.
Veröffentlicht: (2026)

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
von: Brandon K. Bergman, et al.
Veröffentlicht: (2025)

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network
von: Abigail Postema, et al.
Veröffentlicht: (2025)

Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
von: Emily R. Hankosky, et al.
Veröffentlicht: (2025)

Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
von: Jean‐François Yale, et al.
Veröffentlicht: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
von: Matthew J. Armstrong, et al.
Veröffentlicht: (2024)

Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice
von: Danna M. Breen, et al.
Veröffentlicht: (2025)

Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study
von: Testimony Ipaye, et al.
Veröffentlicht: (2025)

Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
von: Kevin Cowart, et al.
Veröffentlicht: (2025)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
von: Iskandar Idris, et al.
Veröffentlicht: (2025)

Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
von: Noga C. Minsky, et al.
Veröffentlicht: (2025)

Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
von: Domenica Rubino, et al.
Veröffentlicht: (2024)

Impact of weight loss on obesity‐related complications and direct healthcare costs in Japan: A modelling study
von: Ataru Igarashi, et al.
Veröffentlicht: (2025)

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
von: Erik Stenberg, et al.
Veröffentlicht: (2024)

A novel, centrally acting mammalian aminosterol, ENT ‐03, induces weight loss in obese and lean rodents
von: Denise Barbut, et al.
Veröffentlicht: (2024)